Vertex Pharmaceuticals (NasdaqGS:VRTX) entered an agreement with WuXi Biologics to co-develop a trispecific T-cell Engager ...
Vertex Pharmaceuticals (NasdaqGS:VRTX) is reassessing its pain management program after disappointing FDA label discussions ...
Revenue growth in 2025 was tempered by lower entitlement growth and a moderation in upsell/cross-sell activity compared to previous periods. Management attributed 2025 customer attrition primarily to ...
Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced ...
ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is among the most profitable healthcare stocks to buy. On January 26, UBS ...
Vertex, Inc. (NASDAQ: VERX) ("Vertex" or the "Company"), a leading global provider of indirect tax solutions, today announced financial results ...
China-based biologics CDMO WuXi Biologics (HKEX: 2269) has signed a license and research services agreement with US biotech Vertex Pharmaceuticals (Nasdaq: VRTX) covering a preclinical trispecific ...
Jupiter Endovascular, Inc. announced completion of patient enrollment in the SPIRARE II pivotal clinical trial evaluating the c ...
YouTube on MSN
I haven't built a keyboard in a long time
Description: Honey finds coupons with one click. Thanks to Honey for sponsoring! Keyboard build (affiliate links below) ...
Rep. Jake Auchincloss of Massachusetts said the Commissioner’s National Priority Voucher program did not receive congressional backing. The FDA has also not yet made disclosures for eight senior ...
Eli Lilly will shell out $2.4 billion to acquire genetic medicine developer Orna Therapeutics and has committed up to $8.85 billion to launch a seventh collaboration with Innovent Biologics. Both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results